Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM2 | Q14416 | 1/20 | 0.49 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | ERCC1 | P07992 | 1/20 | 0.44 |
| ▸ | ERCC4 | Q92889 | 1/20 | 0.44 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.44 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.44 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.44 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.44 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13573037 | 1.00 | GRM2 (0.49) | GRM2PIK3CDALDH1A1KDM4EERCC1 | |
| SCHEMBL19355571 | 0.87 | KCNH2 (0.52) | PIK3CDSMN1; SMN2 | |
| SCHEMBL8292105 | 0.85 | ALDH1A1 (0.49) | PIK3CDALDH1A1CHRM2CHRM4CHRM5 | |
| SCHEMBL12169472 | 0.85 | PIK3CD (0.50) | PIK3CDALDH1A1CHRM2CHRM4CHRM5 | |
| SCHEMBL9424540 | 0.85 | PIK3CD (0.50) | PIK3CDALDH1A1CHRM2CHRM4CHRM5 | |
| SCHEMBL12015723 | 0.85 | PIK3CD (0.50) | PIK3CDALDH1A1CHRM2CHRM4CHRM5 | |
| SCHEMBL16509722 | 0.84 | ALDH1A1 (0.55) | PIK3CDALDH1A1KDM4ESMN1; SMN2 | |
| SCHEMBL23728162 | 0.82 | CHRM1 (0.59) | ERCC1ERCC4CHRM1 | |
| SCHEMBL23747508 | 0.82 | CHRM1 (0.59) | ERCC1ERCC4CHRM1 | |
| SCHEMBL23728122 | 0.82 | CHRM1 (0.59) | ERCC1ERCC4CHRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110306597-A1 | Nicotinamide Derivatives | CRAWFORTH JAMES MICHAEL (GB) | 2011-12-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110306597-A1 | Nicotinamide Derivatives | NNT, NAMPT, NQO1 | GRM2 4236/4885PIK3CD 2681/4885ALDH1A1 172/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.